GlassScriptPhysician profile
Syed W Rizvi
NPI 1396824363
$6,917.15
in general payments reported to CMS, 2019-2025
22 companies · $1,309 in 2025
The $1,309 reported for 2025 was more than what 84% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $347 · 2020: $468 · 2021: $717 · 2022: $875 · 2023: $1,414 · 2024: $1,788 · 2025: $1,309.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,372 · Education: $139.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,372.20 |
| Education | $138.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,054.34 | 2019-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Abbvie INC. | $968.10 | 2021-2025 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $750.50 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $717.30 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Vanda Pharmaceuticals INC. | $493.03 | 2019-2025 | Fanapt, Hetlioz |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $463.92 | 2020-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $426.10 | 2021-2025 | Uzedy, Austedo Xr |
| Supernus Pharmaceuticals, INC. | $400.15 | 2022-2025 | Qelbree, Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $299.66 | 2019-2025 | Trintellix |
| Lundbeck LLC | $299.26 | 2023-2025 | Abilify Asimtufii, Rexulti |
| Neurocrine Biosciences, INC. | $202.85 | 2019-2025 | |
| Sunovion Pharmaceuticals INC. | $182.41 | 2019-2020 | |
| Axsome Therapeutics, INC. | $158.73 | 2023-2025 | Auvelity, Sunosi |
| Corium, LLC | $144.89 | 2022-2025 | Azstarys |
| Allergan, INC. | $107.76 | 2019-2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $96.63 | 2024-2025 | Cobenfy |
| Bausch Health US, LLC | $67.60 | 2021-2025 | Aplenzin |
| Indivior INC. | $21.47 | 2022 | |
| Ironshore Pharmaceuticals INC. | $19.91 | 2019 | |
| Tris Pharma INC | $18.70 | 2024 | |
| Neos Therapeutics, LP | $12.70 | 2023 | Adzenys Xr-Odt |
| Jazz Pharmaceuticals INC. | $11.14 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Syed Rizvi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.